Vicapsys Life Sciences, Inc. is a development stage biotechnology company, which advances proprietary localized immune modulator. The company is headquartered in Cumming, Georgia and currently employs 2 full-time employees. The company went IPO on 2001-07-11. VICAPSYN is the Company’s product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field. The lead product candidate embodiment in transplantation therapy to treat Type 1 Diabetes (T1D) is an encapsulated human islet cell cluster that is intended to restore normal glucose control when implanted into the peritoneal cavity of a patient. The company also develops another product candidate line based on CXCL12 with the trade name of VYBRIN. The clinical applications of VYBRIN are being explored in several areas, including prevention of post-surgical adhesions in abdominal surgery and others.
Follow-Up Questions
Vicapsys Life Sciences Inc 的 CEO 是誰？
Mr. Federico Pier 是 Vicapsys Life Sciences Inc 的 Chief Executive Officer，自 2019 加入公司。
VICP 股票的價格表現如何？
VICP 的當前價格為 $0，在上個交易日 decreased 了 0%。
Vicapsys Life Sciences Inc 的主要業務主題或行業是什麼？
Vicapsys Life Sciences Inc 屬於 Biotechnology 行業，該板塊是 Health Care
